

Krebs Biochemicals & Industries Limited

CIN : L24110AP1991PLC103912



30th July 2018

To,

The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (East)
Mumbai – 400 051

Scrip Code : 524518

Name of Scrip : KREBSBIO

Dear Sir / Madam,

Sub : Outcome of Board Meeting

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 [“SEBI LODR Regulations”], we wish to inform the following outcome of the meeting of the Board of Directors held today, i.e. July 30, 2018 :


- (a) The unaudited financial results for the quarter ended 30th June 2018 along with the Limited Review Report thereon (Enclosed herewith).
- (b) The Board of Directors have considered and approved raising of funds by way of offer and issue of Equity Shares to the members of the Company on rights basis (Rights Issue) at such price and rights entitlement ratio as may be decided by the Board/committee of the Board, for an amount aggregating upto Rs. 25 Crores, subject to necessary approvals and consent as may be necessary / required for compliance of applicable laws, including the provisions of the SEBI (ICDR) Regulations, 2009 as amended, the SEBI LODR Regulations as amended and the Companies Act, 2013 as amended.
- (c) Re-appointment of Mr. Avinash Ravi as Managing Director of the Company for a period of 3 years.
- (d) The notice of 26th Annual General Meeting of the members of the Company scheduled to be held on Monday, 10th September 2018 along with the Board's report and annexures thereto.

Kindly note that the meeting commenced at 10:50AM and concluded at 13:55PM

You are requested to take note of the above.

Thanking you,

Yours faithfully,
For Krebs Biochemicals & Industries Limited


Haritha Vaidyanasi
Company Secretary

